Looking for representation in the Invokana lawsuit? Our experience, expertise, and resources make Hollis Law the ideal partner.
The Hollis Law Firm represents a number of clients all over the United States who have claims against the manufacturers of defective drugs and medical devices, focusing exclusively on these types of cases. The Hollis Law Firm has recovered over 93 million dollars in settlement payments for the hundreds of clients who have been injured by dangerous drugs and medical devices.
If you’ve been affected by this drug, contact us to learn how we can represent you in the Elmiron lawsuit.
Call the Hollis Law Firm at 1-800-701-3672 if you or a loved one has suffered from damages related to the use of this product. All calls and case evaluations are free and carry no obligation. The Hollis Law Firm works on cases on a contingent fee basis, which means we don’t get paid if you don’t get paid. Call 1-800-701-3672 to speak to one of our trained intake specialist so that your potential claim can be reviewed by an attorney at the Hollis Law Firm. The injuries and damages caused by contaminated products will not be uniform; therefore, claims will need to proceed on an individual basis and not as part of a class action.
INVOKANA is commonly prescribed to improve glycemic control (blood sugar) in adults with type 2 Diabetes Mellitus.1
The Institute for Safe Medication Practices, an independent health nonprofit group that monitors FDA reports, has questioned Invokana’s clinical benefits and whether those benefits outweigh its risks. Invokana was approved by the FDA in March of 2013. At the time of FDA approval, Invokana had not been tested in a enough patients for a long enough period of time to answer that question. 2
History of the Case
The U.S. Food and Drug Administration issued a warning in May of 2015 stating that Invokana and similar medicines that treat type 2 Diabetes may lead to a serious condition where the body produces high levels of blood acids called keytones that may require hospitalization.3
In September of 2015, the FDA strengthened the warning for Invokana related to the increased risk of bone fractures and added new information about decreased bone mineral density (relating to the strength of a person’s bones). 4
These warnings came over two years after the drug became available to patients.
Injuries Related to Product
Some injuries that have been linked to Invokana include:
- Ketoacidosis (high levels of blood acids)
- Kidney Failure or Impairment
- Severe Dehydration or Fluid Imbalance
- Increased Risk of Bone Fractures
- Kidney stones
- Urinary Tract Infection
- Abnormal Weight Loss
1 Invokana Product Information
2 ISMP Quarter Watch May 6, 2015
3 FDA Warning Safety Announcement, May 15, 2015
4 FDA Warning Safety Announcement, September 10, 2015
5 ISMP Quarter Watch May 6, 2015